• Explore /
  • Poster
  • / ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC).

ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC).

Abstract Poster

Authors

null

Debu Tripathy

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Debu Tripathy , Sara M. Tolaney , Andrew David Seidman , Carey K. Anders , Nuhad K. Ibrahim , Hope S. Rugo , Chris Twelves , Véronique Diéras , Volkmar Mueller , Alison Hannah , Mary Ann Tagliaferri , Javier Cortés

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Other Breast Cancer Subtypes

Clinical Trial Registration Number

NCT02915744

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS1111)

DOI

10.1200/JCO.2018.36.15_suppl.TPS1111

Abstract #

TPS1111

Poster Bd #

186b

Abstract Disclosures

Similar Posters

First Author: Debu Tripathy

First Author: Peter Andrew Kaufman

First Author: Javier Cortes

First Author: Lee S. Schwartzberg